Nephrectomy after complete response to immune checkpoint inhibitors for metastatic renal cell carcinoma (mRCC): A new surgical challenge?

Authors

Geraldine PIGNOT

Geraldine Pignot

Department of Surgical Oncology, Institut Paoli-Calmettes, Marseille, France

Geraldine Pignot , Antoine Thiery-Vuillemin , Jochen Walz , Herve Lang , Pierre Werle , Loic Balssa , Lionnel Geoffrois , Louis Leblanc , Laurence Albiges , Vincenzo Di Nunno , Karim Bensalah , Sylvain Ladoire , Gwenaelle Gravis , Philippe Barthelemy

Organizations

Department of Surgical Oncology, Institut Paoli-Calmettes, Marseille, France, University Hospital Jean Minjoz, Besançon, France, Institut Paoli-Calmettes, Chirurgie Oncologique 2, Marseille, France, Department of Urology, CHU Strasbourg, Strasbourg University, Strasbourg, France, Urology Department, University Hospital of Strasbourg, Strasbourg, France, Urology Department, Chru Besancon, Besancon, France, Centre Alexis Vautrin, Vandoeuvre-Lès-Nancy, France, Department of Urology, CHRU Nancy, Nancy, France, Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France, Department of medical oncology, Institut Gustave Roussy, Villejuif, France, University Hospital Pontchaillou Service d’urologie CHU Rennes, Université de Rennes, Rennes, France, Department of Medical Oncology, Center GF Leclerc, Dijon, France, Institut Paoli-Calmettes, Marseille, France, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

Research Funding

No funding received
None.

Background: In the current era of Immune checkpoint inhibitors (ICI), the role and timing of nephrectomy in the case of complete response on metastatic sites is still unknown. We aimed to evaluate the feasibility of nephrectomy for residual disease in patients with metastatic renal cell carcinoma (mRCC) and complete response (CR) on metastatic sites following ICI. Methods: Patients who underwent partial or radical nephrectomy after prior ICI between 2015 and 2018 were retrospectively included and clinicopathological data were reviewed. Perioperative data and postoperative outcomes were recorded. Results: Eleven patients without initial cytoreductive nephrectomy at diagnosis underwent delayed nephrectomy after long ICI administration because of complete response on metastatic sites. Median age was 59.8 years [38-67]. All patients had clear cell RCC on the initial biopsy. IMDC prognostic group was intermediate (81.8%) or poor (18.2%). ICI was administered as first-line therapy in 36.4% of cases (4/11) and as second-line option after TKI in 63.6% of cases (7/11). Treatments regimens were: nivolumab + ipilimumab (n = 3), nivolumab + tivozanib (n = 2) or nivolumab alone (n = 6). The median duration of ICI treatment was 10 months (range: 3-38 months) and the mean number of cycles was 27 (range: 6-75). Median operative time was 243 minutes [135-345] and mean blood loss was 909 cc [40-4000]. In 81.8% (n = 9) of the cases, surgeons experienced challenges for finding dissection planes due to inflammatory infiltration. The 30-day Clavien-Dindo postoperative complication rate was 54.6%, including 1 surgery-related death. Pathological report showed lymphocyte and/or macrophage infiltration in 54.6% and complete pathological response in 2 cases. Median follow-up was 15 months, with 73% of patients free from progression and 54% free from systemic treatment at 1 year. Conclusions: Nephrectomy following ICI for mRCC could allow achieving CR in selected patients. Due to technically complexity and complications rates, this surgery should be performed in centers with extensive experience.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer

Track

Renal Cell Cancer

Sub Track

Therapeutics

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr 707)

Abstract #

707

Poster Bd #

H5

Abstract Disclosures

Similar Abstracts

First Author: Regina Barragan-Carrillo

First Author: Sally Leong

First Author: Laeth George